GLPwatch
Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?
Future Cardiol · 2023
Last updated 2026-05-28Tirzepatide is a new diabetes drug that targets two hormones, which may help with blood sugar control and other health benefits. Early research suggests it is likely safe for the heart, but more evidence is needed to confirm its effectiveness for people with diabetes who also have heart failure. The drug is being studied, but current findings are limited.
AI summary of the abstract below.
| Journal | Future Cardiol, 2023 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.34 |
| NIH percentile | 21 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes, Heart Failure |
Abstract
Type 2 diabetes mellitus (T2DM) is a rising pandemic, while cardiovascular disease, including heart failure, represents a frequent concomitance, increasing overall morbidity and mortality and, of course, healthcare cost. Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, constituting a novel treatment option in T2DM. This agent exerts additional effects in addition to improvement in glycemic control, which can be of benefit for individuals with T2DM, especially those at risk for or with established cardiovascular disease or heart failure. Current evidence is limited, although suggestive of the cardiovascular safety of tirzepatide. This article provides an overview of available evidence regarding the use of tirzepatide in T2DM, with emphasis on clinical efficacy.
Verbatim abstract via PubMed 37552101 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.